Combat Medical Raises £2.6 Million in Series A to Advance Cancer Treatment Technology

Combat Medical Secures Series A Funding

Combat Medical, a medical technology company based in London, has successfully raised £2.6 million in a Series A funding round. The funding aims to advance their hyperthermic technologies, which are currently used in cancer treatments across over 40 countries.

Funding Details

The Series A round was led by the T&J Meyer Family Foundation, with additional investments from Varia Ventures and NW Angel Fund. These funds will support the company's ongoing efforts to bring its innovative therapies to market, particularly focusing on its hyperthermic intravesical chemotherapy treatment, known as HIVEC.

Advancing HIVEC Therapy

Combat Medical is working towards FDA approval for its HIVEC treatment, which is designed to improve chemotherapy delivery by heating therapeutic agents before administration. CEO Edward Bruce-White explained that the technology offers a "safe and well-tolerated, bladder-sparing alternative" to radical cystectomy for patients with BCG-unresponsive non-muscle-invasive bladder cancer.

Use of Funds

The newly acquired funds will primarily be used to advance the HIVEC therapy through phase three clinical trials, a crucial step towards securing FDA registration. The trials aim to evaluate the safety and efficacy of the treatment, potentially offering a less invasive option for patients with limited alternatives.

Market Impact and Future Plans

Combat Medical has already installed over 350 systems globally and completed more than 100,000 HIVEC treatments. The company plans to use future financings to complete FDA registration and expand operations, particularly targeting the U.S. market. Additionally, they are looking to develop further applications of their hyperthermic technology, including treatments for advanced bladder and peritoneal cancers.

Investor Confidence

Balint Nemeth from the T&J Meyer Family Foundation expressed confidence in Combat Medical's potential to "disrupt current treatment standards" and improve patient outcomes. The foundation's support, alongside other investors, will help the company progress through clinical trials and move closer to broader commercialization.

Combat Medical's recent funding marks a significant step in their mission to transform cancer treatment and provide more accessible care options to patients worldwide.